Use of a decision analysis model to assess the cost-effectiveness of 18F-FDG PET in the management of metachronous liver metastases of colorectal cancer

Journal of Nuclear Medicine

Volumn 46, Issue 12, 2005, Pages 2020-2028

  Lejeune, Catherine ^a,b   Bismuth, Marie J ^c   Conroy, Thierry ^d,e   Zanni, Catherine ^f   Bey, Pierre ^g   Bedenne, Laurent ^b   Faivre, Jean ^a,b   Arveux, Patrick ^a,b,h   Guillemin, Francis ^e  

^a INSERM   (France)

^b UNIVERSITÉ DE BOURGOGNE   (France)

^c DIJON UNIVERSITY HOSPITAL   (France)

^d Ctr Reg Lutte Contre le Cancer A   (France)

^e UNIVERSITÉ DE LORRAINE   (France)

^f Caisse Nationale d'Assurance Maladie des Travailleurs Salaries   (France)

^g INSTITUT CURIE   (France)

^h Centre F Leclerc   (France)

Author keywords

Cost effectiveness; Decision modeling; Metachromous metastases; PET; Program evaluation

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT;

AGED; ARTICLE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CASE REPORT; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC IMAGING; HEALTH INSURANCE; HISTOPATHOLOGY; HOSPITAL COST; HUMAN; INTERMETHOD COMPARISON; LIVER BIOPSY; LIVER METASTASIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; COLORECTAL TUMOR; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; ECONOMICS; LIVER TUMOR; METASTASIS; METHODOLOGY; NEOPLASM; PATHOLOGY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TIME; TREATMENT OUTCOME;

COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 33644875648     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Remontet L, Esteve J, Bouvier AM, et al. Cancer incidence and mortality in France over the period 1978-2000. Rev Epidemiol Sante Publique. 2003;51:3-30.
2. Faivre-Finn C, Bouvier-Benhamiche AM, Phelip JM, Manfredi S, Dancourt V, Faivre J. Colon cancer in France: evidence for improvement in management and survival. Gut. 2002;51:60-64.
3. Manfredi S, Benhamiche AM, Meny B, Cheynel N, Rat P, Faivre J. Population-based study of factors influencing occurrence and prognosis of local recurrence after surgery for rectal cancer. Br J Surg. 2001;88:1221-1227.
4. Faivre J, Manfredi S, Bouvier AM. Epidemiology of colorectal cancer liver metastases. Bull Acad Natl Med. 2003;187:815-822.
5. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309-318.
6. Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver: a prognostic scoring system to improve case selection, based on 1568 patients-French Surgical Association. Cancer. 1996;77:1254-1262.
7. Zerhouni EA, Rutter C, Hamilton SR, et al. CT and MR imaging in the staging of colorectal carcinoma: report of the Radiology Diagnostic Oncology Group II. Radiology. 1996;200:443-451.
8. Valls C, Andia E, Sanchez A, et al. Hepatic metastases from colorectal cancer: preoperative detection and assessment of resectability with helical CT. Radiology. 2001;218:55-60.
9. Flamen P, Stroobants S, Van Cutsem E, et al. Additional value of whole-body positron emission tomography with fluorine-18-2-nuoro-2-deoxy-D- glucose in recurrent colorectal cancer. J Clin Oncol. 1999;17:894-901.
10. Ruhlmann J, Schomburg A, Bender H. Fluorodeoxyglucose whole-body positron emission tomography in colorectal patients studied in routine daily practice. Dis Colon Rectum. 1997;40:1195-1204.
11. Gambhir SS, Valk P, Sheperd J, Hoh C, Allen M, Phelps ME. Cost effective analysis modeling of the role of FDG PET in the management of patients with recurrent colorectal cancer [abstract]. J Nucl Med. 1997;38(suppl):90P.
12. Park KC, Schwimmer J, Shepherd JE, et al. Decision analysis for the cost-effective management of recurrent colorectal cancer. Ann Surg. 2001;233:310-319.
13. Conroy T, Gory-Delabaere G, Adenis A, et al. Clinical practice guideline: 2003 update of standards, options and recommendations for first line palliative chemotherapy in patients with metastatic colorectal cancer (summary report). Bull Cancer. 2004;91:759-768.
14. Fornari F, Civardi G, Cavanna L, et al. Ultrasonically guided fine-needle aspiration biopsy: a highly diagnostic procedure for hepatic tumors. Am J Gastroenterol. 1990;85:1009-1013.
15. Kondo H, Kanematsu M, Hoshi H, et al. Preoperative detection of malignant hepatic tumors: comparison of combined methods of MR imaging with combined methods of CT. AJR. 2000;174:947-954.
16. Ogunbiyi OA, Flanagan FL, Dehdashti F, et al. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. Ann Surg Oncol. 1997;4:613-620.
17. Delbeke D, Vitola JV, Sandler MP. Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med. 1997;38:1196-1201.
18. Tempero MA, Williams CA, Anderson JC. The value of hepatic ultrasound and biochemical liver tests in screening for liver metastases. J Clin Oncol. 1986;4:1074-1078.
19. Valls C, Lopez E, Guma A, et al. Helical CT versus CT arterial portography in the detection of hepatic metastasis of colorectal carcinoma. AJR. 1998;170:1341-1347.
20. Ruers TJ, Langenhoff BS, Neeleman N, et al. Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J Clin Oncol. 2002;20:388-395.
21. Low RN, Semelka RC, Worawattanakul S, Alzate GD, Sigeti JS. Extrahepatic abdominal imaging in patients with malignancy: comparison of MR imaging and helical CT, with subsequent surgical correlation. Radiology. 1999;210:625-632.
22. Small WC, Mehard WB, Langmo LS, et al. Preoperative determination of the resectability of hepatic tumors: efficacy of CT during arterial portography. AJR. 1993;161:319-322.
23. Steele G Jr, Bleday R, Mayer RJ, Lindblad A, Petrelli N, Weaver D. A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: Gastrointestinal Tumor Study Group Protocol 6584. J Clin Oncol. 1991;9:1105-1112.
24. Malafosse R, Penna C, Sa Cunha A, Nordlinger B. Surgical management of hepatic metastases from colorectal malignancies. Ann Oncol. 2001;12:887-894.
25. Beck JR, Kassirer JP, Pauker SG. A convenient approximation of life expectancy (the "DEALE"): validation of the method. Am J Med. 1982;73:883-888.
26. Beck JR, Pauker SG, Gottlieb JE, Klein K, Kassirer JP. A convenient approximation of life expectancy (the "DEALE"): use in medical decision-making. Am J Med. 1982;73:889-897.
27. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ. 1996;313:275-283.
28. Consensus conference: prevention screening and management of the colonic cancers [in French]. Gastroenterol Clin Biol. 1998;22:S275-S288.
29. Gallix B. What exams should be ordered for the pretherapeutic work-up? Criteria of quality and expected results. Gastroenterol Clin Biol. 2003;27(special no. 2):B9-B10, B25-B40.
30. Vergara V, Garripoli A, Marucci MM, Bonino F, Capussotti L. Colon cancer seeding after percutaneous fine needle aspiration of liver metastasis. J Hepatol. 1993;18:276-278.
31. White TJ, Roy-Choudhury SH, Breen DJ, et al. Percutaneous radiofrequency ablation of colorectal hepatic metastases: initial experience-an adjunct technique to systemic chemotherapy for those with inoperable colorectal hepatic metastases. Dig Surg. 2004;21:314-320.
32. Lencioni R, Crocetti L, Cioni D, Della Pina C, Bartolozzi C. Percutaneous radiofrequency ablation of hepatic colorectal metastases: technique, indications, results, and new promises. Invest Radiol. 2004;39:689-697.
33. ANAES. The therapeutic of liver metastases of colorectal cancer [in French], October 2002. Available at: http://www.anaes.fr/anaes/Publications.nsf/ wEdition/RE_LILF-5J9DUW. Accessed April 12, 2005.
34. Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg. 2004;240:438-450.
35. 18F]fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg. 1999;134:503-511.
36. 18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver. Arch Surg. 1996;131:703-707.
37. Arulampalam T, Costa D, Visvikis D, Boulos P, Taylor I, Ell P. The impact of FDG-PET on the management algorithm for recurrent colorectal cancer. Eur J Nucl Med. 2001;28:1758-1765.